FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379335175> ?p ?o ?g. }

• W4379335175 endingPage "7000" @default.
• W4379335175 startingPage "7000" @default.
• W4379335175 abstract "7000 Background: Obe-cel is an autologous CD19CAR with a fast off-rate CD19 binding domain designed to reduce CAR-T immunotoxicity and improve persistence. Its clinical activity has been tested in r/r paediatric and adult B-ALL trials (CARPALL, Ghorashian S et al., Nat Med 2019; ALLCAR19, Roddie C et al., JCO 2021) and more recently in adults with r/r B-cell malignancies (NCT02935257). Here, we present data from adult r/r B-ALL patients treated with obe-cel in the pivotal FELIX study (NCT04404660). Methods: FELIX is an open-label, multi-centre, global, single-arm Phase Ib/II study enrolling r/r B-ALL patients with morphological disease (≥5% BM blasts), measurable residual disease (MRD) (≥0.1% to < 5% BM blasts), or isolated extramedullary disease (Cohorts A, B and C). CAR-T products were generated using an automated closed process from fresh leukapheresate. Patients underwent bridging therapy as necessary and lymphodepletion with fludarabine (4x30mg/m2) and cyclophosphamide (2x500mg/m2). Patients received a target dose of 410E+6 CAR T cells as a split dose on Day 1 and Day 10. The dosing schedule is based on the % BM blasts performed locally prior to the pre-conditioning. Primary endpoint was overall remission rate (ORR) defined as proportion of patients achieving CR/CRi by central assessment. Results: As of 9 th September 2022, a pre-specified interim analysis was conducted based on the first 50 patients infused in Cohort A who have been followed for 3 months or discontinued before month 3. The median age was 50 years (range 20-81), 22% had Ph+ B-ALL. The median number of prior lines of treatment was 2 (range 1-5), 42% underwent prior transplant. At screening, patients had a median of 55% BM blasts (range 6-96%) and 26% had EMD. The geometric mean of peak CAR expansion was 126147.6 copies/ug genomic DNA. Persistence was ongoing in majority of responders at last follow-up. Based on central assessment, the CR/CRi was 70% [95% CI: 55%, 82%] (p-value < 0.0001). As of 9 th September 2022, a total of 92 patients received obe-cel and were evaluable for safety. 63% developed any grade CRS (3% Grade ≥3) at a median of 9 days post-infusion and a median duration of 5 days. Any grade ICANS was observed in 23% (8% Grade ≥3) at a median of 15 days post-infusion and of median duration 8 days. Other common Grade≥3 adverse events regardless of causality were febrile neutropenia (25%) and anaemia (20%). Conclusions: The pre-specified interim analysis of the FELIX study demonstrated that obe-cel for adult r/r B-ALL is safe with low rates of Grade >3 CRS and/or ICANS, even in patients with high burden disease. Obe-cel is effective with high CR/CRi rates and ongoing CAR T persistence in the majority of responders. The trial has completed dosing of all patients in Cohort A. Additional data and longer follow up will be reported at the conference. Clinical trial information: NCT04404660 ." @default.
• W4379335175 created "2023-06-05" @default.
• W4379335175 creator A5000083234 @default.
• W4379335175 creator A5006657942 @default.
• W4379335175 creator A5009665482 @default.
• W4379335175 creator A5011452918 @default.
• W4379335175 creator A5014618029 @default.
• W4379335175 creator A5016395549 @default.
• W4379335175 creator A5019014469 @default.
• W4379335175 creator A5022750427 @default.
• W4379335175 creator A5026456735 @default.
• W4379335175 creator A5040138933 @default.
• W4379335175 creator A5049385583 @default.
• W4379335175 creator A5055419327 @default.
• W4379335175 creator A5063345064 @default.
• W4379335175 creator A5064294460 @default.
• W4379335175 creator A5071608606 @default.
• W4379335175 creator A5071733656 @default.
• W4379335175 creator A5082924494 @default.
• W4379335175 creator A5085514831 @default.
• W4379335175 creator A5089893290 @default.
• W4379335175 date "2023-06-01" @default.
• W4379335175 modified "2023-10-18" @default.
• W4379335175 title "Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study." @default.
• W4379335175 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7000" @default.
• W4379335175 hasPublicationYear "2023" @default.
• W4379335175 type Work @default.
• W4379335175 citedByCount "3" @default.
• W4379335175 countsByYear W43793351752023 @default.
• W4379335175 crossrefType "journal-article" @default.
• W4379335175 hasAuthorship W4379335175A5000083234 @default.
• W4379335175 hasAuthorship W4379335175A5006657942 @default.
• W4379335175 hasAuthorship W4379335175A5009665482 @default.
• W4379335175 hasAuthorship W4379335175A5011452918 @default.
• W4379335175 hasAuthorship W4379335175A5014618029 @default.
• W4379335175 hasAuthorship W4379335175A5016395549 @default.
• W4379335175 hasAuthorship W4379335175A5019014469 @default.
• W4379335175 hasAuthorship W4379335175A5022750427 @default.
• W4379335175 hasAuthorship W4379335175A5026456735 @default.
• W4379335175 hasAuthorship W4379335175A5040138933 @default.
• W4379335175 hasAuthorship W4379335175A5049385583 @default.
• W4379335175 hasAuthorship W4379335175A5055419327 @default.
• W4379335175 hasAuthorship W4379335175A5063345064 @default.
• W4379335175 hasAuthorship W4379335175A5064294460 @default.
• W4379335175 hasAuthorship W4379335175A5071608606 @default.
• W4379335175 hasAuthorship W4379335175A5071733656 @default.
• W4379335175 hasAuthorship W4379335175A5082924494 @default.
• W4379335175 hasAuthorship W4379335175A5085514831 @default.
• W4379335175 hasAuthorship W4379335175A5089893290 @default.
• W4379335175 hasConcept C121332964 @default.
• W4379335175 hasConcept C126322002 @default.
• W4379335175 hasConcept C126894567 @default.
• W4379335175 hasConcept C141071460 @default.
• W4379335175 hasConcept C142424586 @default.
• W4379335175 hasConcept C203092338 @default.
• W4379335175 hasConcept C2776694085 @default.
• W4379335175 hasConcept C2776755627 @default.
• W4379335175 hasConcept C2777288759 @default.
• W4379335175 hasConcept C2778461978 @default.
• W4379335175 hasConcept C2779263901 @default.
• W4379335175 hasConcept C2779823535 @default.
• W4379335175 hasConcept C31760486 @default.
• W4379335175 hasConcept C535046627 @default.
• W4379335175 hasConcept C71924100 @default.
• W4379335175 hasConcept C72563966 @default.
• W4379335175 hasConcept C87355193 @default.
• W4379335175 hasConcept C90924648 @default.
• W4379335175 hasConceptScore W4379335175C121332964 @default.
• W4379335175 hasConceptScore W4379335175C126322002 @default.
• W4379335175 hasConceptScore W4379335175C126894567 @default.
• W4379335175 hasConceptScore W4379335175C141071460 @default.
• W4379335175 hasConceptScore W4379335175C142424586 @default.
• W4379335175 hasConceptScore W4379335175C203092338 @default.
• W4379335175 hasConceptScore W4379335175C2776694085 @default.
• W4379335175 hasConceptScore W4379335175C2776755627 @default.
• W4379335175 hasConceptScore W4379335175C2777288759 @default.
• W4379335175 hasConceptScore W4379335175C2778461978 @default.
• W4379335175 hasConceptScore W4379335175C2779263901 @default.
• W4379335175 hasConceptScore W4379335175C2779823535 @default.
• W4379335175 hasConceptScore W4379335175C31760486 @default.
• W4379335175 hasConceptScore W4379335175C535046627 @default.
• W4379335175 hasConceptScore W4379335175C71924100 @default.
• W4379335175 hasConceptScore W4379335175C72563966 @default.
• W4379335175 hasConceptScore W4379335175C87355193 @default.
• W4379335175 hasConceptScore W4379335175C90924648 @default.
• W4379335175 hasIssue "16_suppl" @default.
• W4379335175 hasLocation W43793351751 @default.
• W4379335175 hasOpenAccess W4379335175 @default.
• W4379335175 hasPrimaryLocation W43793351751 @default.
• W4379335175 hasRelatedWork W2023136491 @default.
• W4379335175 hasRelatedWork W2085877601 @default.
• W4379335175 hasRelatedWork W2112430411 @default.
• W4379335175 hasRelatedWork W2137597826 @default.
• W4379335175 hasRelatedWork W2362661449 @default.
• W4379335175 hasRelatedWork W2374997696 @default.
• W4379335175 hasRelatedWork W2528057197 @default.
• W4379335175 hasRelatedWork W2557725129 @default.
• W4379335175 hasRelatedWork W2921951444 @default.

• next